Boan Biotech Receives IND Clearance in China for BA2201, a Novel TL1A/IL-23 Bispecific Antibody for Inflammatory Bowel Disease

Yantai, China, November 6, 2026 – Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has cleared the Investig...

VOLUNTARY ANNOUNCEMENT CDE APPROVAL OF IND APPLICATION IN CHINA FOR BA2201, A TL1A/IL-23 BISPECIFIC ANTIBODY FOR THE TREATMENT OF IBD (105KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026

VOLUNTARY ANNOUNCEMENT THE COMPANY ENTERS INTO LICENSING AGREEMENT FOR DENOSUMAB INJECTION 60 MG IN JAPAN

Boan Biotech Enters into Licensing Agreement for Denosumab Injection 60 mg in Japan

Yantai, China, October 30, 2026 – Boan Biotech announced today that it has entered into a licensing agreement with a partner for BA6101, a 60 mg denosumab injection, in Japan. Under the agreemen...

Boan Biotech Announces First Subject Enrolled in Phase I Clinical Trial of BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein) in China

Yantai, October 22, 2026 – Boan Biotech announced today that the first subject has been enrolled in a Phase I clinical trial of BA1203 in China. BA1203 is an investigational anti-PD-1/IL-2 antib...

VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLED IN PHASE I CLINICAL TRIAL OF BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN) IN CHINA

CONTINUING CONNECTED TRANSACTIONS PROMOTION COOPERATION AGREEMENT

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

INTERIM REPORT 2026